JoTo PR has announced an engagement with NuView Life Sciences, Inc (http://nuviewinfo.com/site/3/). (NVLS), a biotechnology leader in precision cancer diagnostics and therapeutics based in Park City, Utah.

With medical headlines declaring that there are too many cancer diagnostics tests that are considered invasive, unhealthy and pricey, consumers driving hospital ratings have made a case for precision medicine.1

NVLS was founded in 2005 as a Delaware Corporation with the strategic objective to develop and commercialize novel Positron Emission Tomography (PET) imaging agents. NVLS has two wholly-owned, independently operating subsidiaries: One being the NuView diagnostics LLC (NDx) that develops the liquid biopsy diagnostic applications including the in vitro prostate/bladder cancer urine screen kit. The other, a US Radiopharmaceutical Corporation (USR), an FDA-registered manufacturer and distributor facility of medical isotopes.

In the U.S., breast cancer and prostate/bladder cancer are the most common cancer among women and men of all races and ethnicities respectively. NuView’s technology will improve the specificity of early stage breast cancers and significantly reduce the number of negative biopsies performed each year. Their in vitro diagnostic, which uses a compound visible under a microscope, offers a cost-effective, non-invasive test of voided urine that offsets the invasive nature of the prostate biopsy procedure.

In 2007, NuView licensed the rights to develop and commercialize its first platform technology, NV‐VPAC1 (http://nuviewinfo.com/site/3/vpac1/#breast), and is currently developing in vitro and in vivo diagnostic applications of the technology. NV-VPAC1 is a series of peptide analogs that target the vasoactive intestinal peptide receptor type 1. The receptor becomes overexpressed in certain key malignancies including breast, prostate, colon, bladder and endometrial cancer. Attaching a molecular imaging or therapeutic component to a NV-VPAC1 peptide enables NuView to develop a series of precisely targeted products that may be used in the diagnosis and treatment of cancer.

“NuView Life Sciences has a very important pharma-economic story to tell. They have succeeded in their research and plan to begin FDA clinical trials in the coming months”

said Karla Jo Helms, chief executive officer, JoTo PR (http://www.jotopr.com/).“We look forward to partnering with their team as they champion the options in precision diagnosis of cancer and therapeutics.”

JoTo PR has a rich history in innovative business PR solutions and provides services to national and international organizations. The PR firm is a pioneer in the PR industry, blending traditional PR expertise with high technology so as to harness the advantages of both worlds – traditional and new. JoTo PR specializes in the healthcare, finance and technology sectors but has worked for a variety of industries and non-profits, using a proprietary process to find, relay and render to the news consistently what makes client information valuable to their respective industries.

For more information, visit JoTo PR online at http://www.jotopr.com/.